Ramipril - Altace has received FDA approval to launch into the
US market in June 2000 after excessive clinical trials. The pill was finally approved for present and future treatment. ACE inhibitor is a drug, which is used particularly in controlling of high blood pressure. Ramipril is marketed by Monarch Pharmaceuticals, Inc which is a subsidiary of King Pharmaceuticals. It is commonly referred to as an ACE. This angiotensin converting enzyme was originally approved by the FDA in the year 1991 to use it for treating hypertension in patients and then later FDA approved for the cure of conditions like congestive heart failure that often appear in patients that go through severe heart attacks.

Altace is among the pioneers of ACE inhibitors that have received FDA approval. Altace reduces the danger of stroke and myocardial infarction that result in death from cardiovascular reasons. Particularly in patients over 55 years of age and having a history with coronary artery disease or strokes, or in some cases, peripheral vascular disease coupling with diabetes and or other types of cardiovascular risk issues that arise mostly from cigarette smoking.

Altace® (ramipril) received approval from the U.S. Food and Drug Administration (FDA) in 2000, after experimented on patients who were above 55 who had a record of coronary artery disease or stroke or have been drinking and smoking in their lives; the study resulted in reducing the risk of stroke, heart attack and death from cardiovascular causes. Future use of the drug also shows positive and promising result. The manufacturer of this drug is not too worried about the sales for the drug is effective and has proved its worth.